Loading
A phase 3 trial of Fruquintinib, Sintilimab, Paclitaxel / nab-paclitaxel in endometrial cancer, run by Hutchmed, now recruiting.
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer is a phase 3 interventional study registered as NCT06584032 by Hutchmed, with 412 participants planned, started 2024-12-12 and due to reach its primary completion in 2029-01-08. Interventions recorded: fruquintinib, sintilimab, paclitaxel, doxorubicin. Conditions listed: Advanced Endometrial Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced or recurrent endometrial cancer, Anti-angiogenic therapy, Endometrial cancer, Monoclonal antibodies.
Shares Fruquintinib, Sintilimab, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Fruquintinib, Sintilimab, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Fruquintinib, Sintilimab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
Shares Hutchmed, Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Advanced or recurrent endometrial cancer, Doxorubicin, Endometrial cancer, Paclitaxel / nab-paclitaxel.
Shares Advanced or recurrent endometrial cancer, Anti-angiogenic therapy, Endometrial cancer, Monoclonal antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/